Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07220408

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.

The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Allergic Conjunctivitis Conjunctival Diseases Conjunctivitis Conjunctivitis, Allergic Eye Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Advancing Vision Research

Smyrna, Tennessee, 37167, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 18 years or older
  • Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
  • Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
  • Calculated best-corrected visual activity
  • Positive bilateral CAC reaction

Exclusion criteria

  • Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
  • Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
  • Any ongoing ocular infection (bacterial, viral or fungal)

Treatment and study plan

TL-925

Drug

TL-925 is an eye drop.

Placebo

Drug

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Primary outcomes

  1. Ocular Itching

    Time frame: 3, 5 and 7 minutes after CAC

    Ocular itching score will be reported by the subject at 3 timepoints after CAC at Visits 4d , 5d, and 6c.

  2. Conjunctival Redness

    Time frame: 7, 15 and 20 minutes after CAC

    Conjunctival redness score will be evaluated by the investigator at 3 timepoints after CAC at Visits 4d, 5d, and 6c.

Study contacts

Contact information is provided by the study sponsor or research team.

John Mei

CONTACT

[email protected]

650-542-0136

Yulia Khalina

CONTACT

[email protected]

908-656-2799

Sponsors and collaborators

Lead sponsor

Telios Pharma, Inc.

Industry

Registry information

Official study title

A Single Center, Randomized, Double-masked, Vehicle Controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Seasonal Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 23, 2025
Registry last updated
Nov 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.